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Introduction 
 It is estimated that about 50% of the United States population has used at least one 
prescription drug within the previous month, and roughly 22% has used three or more (CDC 
website, 2015). However, adherence to medications continues to be a major issue. A recent study 
found that 18% of cardiac prescriptions were not filled by patients four months after a major 
coronary event (Jackevicius, 2008). Other research has found that only 37% of patients are 
adherent to statin therapy (Wu, 2011) and only 66% to antidiabetic medications (Yeaw, 2009). 
High levels of medication adherence for long-term conditions can reduce rates of hospitalization 
and lower overall healthcare costs (Wu, 2011; Sokol, 2005). However, the question of how to 
increase medication adherence remains unanswered.  
 The World Health Organization identifies five factors contributing to medication 
nonadherence: economic, health-system, patient-related, condition-related, and therapy-related. 
Among therapy-related factors, adverse effects of the drug are a major obstacle (Sabate, 2003). 
The presence of adverse effects has been shown to decrease adherence to a wide variety of drugs, 
including glucocorticoids (Arena, 2010) and antidepressants (Weissman, 2012). Nearly all drugs 
carry the risk of unwanted side effects, with varying degrees of likelihood and severity; however, 
most adverse effects are relatively rare or can be mitigated with proper counseling and 
monitoring. For instance, medications that cause stomach upset are often recommended to be 
taken with food to prevent irritation to the GI tract and the resultant nausea. Pharmacists can play 
a significant role in preventing adverse effects from occurring in their patients, or at least 
providing strategies to minimize or treat the adverse effects. Direct pharmacist counseling has 
been shown to lower the rate of preventable adverse drug events following hospital discharge 
(Schnipper, 2006). In addition, recent studies have shown pharmacist interventions and 
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counseling to yield improvements in adherence to lipid-lowering therapies (Hedegaard, 2015) 
and asthma inhalers (Naik-Panvelkar, 2015). 
Along with proper counseling, it is critical that patients understand the relationship between 
the actual likelihood of an adverse effect occurring and the possibility of themselves 
experiencing the adverse effect after taking the drug. Knowing the risks associated with a drug 
are important for the patient to make an informed decision on whether or not they want to take a 
medication. Prior research has shown numerical adverse effect information to be easier for 
patients to accurately comprehend compared to non-numerical information (Peters, 2014; West, 
2013). Patients tend to overestimate the likelihood of an adverse effect when given non-
numerical information, such as “common” or “rare,” compared to a percentage or ratio, such as 
“10% of patients” or “1 in 10 patients” (Knapp, 2005) and when given combined non-numerical 
and numerical information rather than numerical information alone (Knapp, 2015).  
The objective of this study is to assess how two factors (the likelihood of the adverse effect 
occurring, and pharmacist counseling on prevention of an adverse effect) affect patients’ 
perceptions of the safety of a newly prescribed medication and the likelihood that patients will 
take the medication. The study hypotheses were as follows: (1) individuals will be most willing 
to use the medication and will consider it safest when the probability of a side-effect is low, (2) 
individuals will be most willing to use the medication and consider it safest when counseling on 
how to prevent the side-effect is provided, and (3) there will be an interaction between the 
provision of probability and prevention information such that, among individuals given 
prevention information, perceptions of medication safety and willingness to use the medication 
will not be affected by the probability of experiencing the side-effect. 
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Materials and Methods 
 The study used a 3 x 3 experimental research design. All participants read a brief, 
hypothetical scenario that began as follows:  
“Imagine you have recently been experiencing episodes of wheezing and shortness of 
breath. You visit your family doctor and he tells you that you have asthma. He assures 
you that asthma is treatable and writes you a prescription for an inhaler called Cradulox. 
The directions say ‘inhale one puff twice daily.’ Your doctor refers you to your local 
pharmacy. The pharmacist fills your prescription, explains how to use the inhaler, and 
states that it can cause fungal infections in the throat.”   
The next portion of the scenario differed across experimental groups. The two experimental 
factors manipulated were (1) probability of developing a fungal infection (i.e., 5%, 20%, no 
probability mentioned) and (2) strategy for preventing fungal infections (i.e., no prevention 
strategy discussed, prevention strategy discussed, prevention strategy discussed including an 
explanation of how the prevention strategy reduces the risk of experiencing a fungal infection) 
(see Table 1). In all groups, the scenario ended with the following statement: “The pharmacist 
tells you that there are five refills available on the prescription, and to call the pharmacy if you 
have any questions.” After reading the scenario, participants answered seven questions 
concerning their perception of the safety and effectiveness of the hypothetical medication. 
Participants were able to refer to the scenario while answering the questions. 
The survey was created using Qualtrics software and study participants were recruited 
through Amazon Mechanical Turk. A total of 633 Mechanical Turk workers agreed to participate 
and accessed the survey. However, 32 individuals failed an attention check within the survey and 
were therefore excluded. The attention check question instructed participants to select 
“Somewhat likely” as the response to the question. Selecting any other response invoked a skip 
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pattern within Qualtrics that prevented the individual from completing the remainder of the 
survey. Study participants were adults aged 18 years or older and living in the United States. All 
data was collected on June 1, 2015. 
Measures 
 Primary Outcome Variables. The primary outcome variables were: (1) willingness to 
take the medication and (2) perceived medication safety. Willingness to take the medication was 
assessed by asking: “If you had asthma and your doctor prescribed this medication for you, how 
likely is it that you would take it?” Participants answered on a 7-point scale ranging from Very 
Unlikely to Very Likely. Participants were also asked: “What is the most important reason for 
how likely or unlikely you would be to take this medication?” The following options were 
provided: (a) the adverse events are not very serious, (b) any serious adverse events are very 
unlikely, (c) prefer to avoid taking medications and will do something else, (d) a lot of people 
will get fungal infections and I don’t want to be one of them, (e) I would like to get rid of the 
wheezing and shortness of breath, and (f) none of the above. This measure was modeled after a 
question developed by Peters et al. (2014). Perceived medication safety was assessed by asking: 
“How safe or dangerous is this medication?” Participants answered on a 7-point scale ranging 
from Very Safe to Very Dangerous. 
 Secondary Outcome Variables.  Four secondary outcome variables were assessed. First, 
participants were asked to respond to the following statement: “The potential benefits of taking 
this medication outweigh the potential risks.” Responses were recorded on a 7-point scale 
ranging from Strongly Agree to Strongly Disagree. Next, participants were asked, “If you had 
asthma and took this medication, how likely is the medication to help you?” Responses were 
recorded on a 7-point scale ranging from Very Likely to Very Unlikely. The final two variables 
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used the same response scale, and were as follows: “If you had asthma and took this medication, 
how likely is the medication to cause side effects?” and “How likely are you to recommend this 
medication to somebody else with asthma?”  
Demographics. The following demographic information was assessed: age, gender, race, 
education, and status as a healthcare provider. In addition, participants were asked to rate their 
own overall health, with the options being poor, fair, good, very good, or excellent. They were 
also asked whether they were currently taking a prescription medication regularly and whether 
they had ever had a serious side effect from a medication. 
 Manipulation Check Questions. The final three items in the survey were designed as 
manipulation checks. Participants were not able to view the scenario when answering these 
questions. First, participants were asked: “If 100 people used Cradulox, how many do you think 
would develop a fungal infection of the throat.” Second, participants were asked to respond to 
the following statement: “There are things that people can do to reduce the risk of developing a 
fungal infection when using Cradulox.” Responses were recorded on a 7-point scale ranging 
from Strongly Agree to Strongly Disagree. Finally, participants were asked, “Which of the 
following is most likely to reduce the risk of developing a fungal infection when using 
Cradulox?” The available choices were (a) taking the medication with food, (b) rinsing your 
mouth out with cool water following use, (c) using the medication at night prior to bedtime, and 
(d) none of the above. 
Statistical Analysis 
 All analyses were completed using PC-SAS version 9.4 (SAS Institute Inc., 2013). 
Descriptive statistics were used to summarize the participant characteristics. Student t-tests and 
chi-square tests were conducted to determine if the experimental groups differed with respect to 
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any of the demographic characteristics assessed. To determine the effectiveness of the 
experimental manipulations, we calculated the percentage of participants in the low and high 
probability conditions who responded correctly to the question asking, “If 100 people used 
Cradulox, how many do you think would develop a fungal infection of the throat?” The “correct” 
answer corresponded to participants’ group assignment and differed for those in the low and high 
probability conditions. We also calculated the percentage of participants in each group who 
correctly responded that the risk of fungal infections could be reduced by rinsing one’s mouth 
out with cool water following use. Linear regression was used to assess the effect of the two 
experimental conditions (i.e. probability of fungal infections and prevention information to 
reduce risk) on the primary and secondary outcome variables. A separate regression model was 
run for each outcome variable. Each model included a term indexing the multiplicative 
interaction between the two experimental conditions. If the interaction term was not statistically 
significant, the model was rerun with the interaction term deleted. Significant main effects were 
followed up via independent group t-tests to evaluate between group differences.  
Results 
 The mean age of participants (n = 601) was 33 years (SD = 10.9) and most identified as 
white (78.2%), male (60.1%), and 52.1% had a bachelor’s degree or higher. Participants reported 
their health as poor (1.83%), fair (9.32%), good (29.6%), very good (41.8%), or excellent 
(17.5%). Only 22 participants (3.7%) identified themselves as a healthcare professional. About a 
quarter (26.8%) of participants reported using a regular prescription medication, and 16% 
reported having experienced a serious side effect from a medication. None of the participant 
characteristics differed significantly across the experimental conditions.  
Manipulation Checks 
8 
 
 A total of 169 (87.6%) participants in the high probability group correctly answered that 
20 out of 100 people would develop a fungal infection when using Cradulox. Likewise, 179 
(86.9%) participants in the low probability group correctly answered that 5 out of 100 people 
would develop an infection. Among participants who were not given any probability 
information, the median probability estimate was 5.0 (Mean = 12.4, SD = 15.3, IQR=3.0-15.0).  
Participants given prevention information or prevention information plus an explanation 
were more likely to agree that there are things people can do to reduce the risk of developing a 
fungal infection when using Cradulox, with means of 5.3 and 5.4, respectively, compared to 2.9 
in the no prevention information group (p < 0.0001). Almost all participants who were given 
either prevention information (96.7%) or prevention information plus an explanation (97.5%) 
correctly indicated that the risk of developing a fungal infection while using Cradulox could be 
reduced by rinsing one’s mouth with cool water following use. Of the participants given no 
prevention information, 38.7% answered correctly. 
Effect of Probability Information 
 The interaction between the two experimental conditions (probability of fungal infection 
and prevention information) was not statistically significant for any of the primary or secondary 
outcome variables. Therefore, this section and the next section focus on the main effects of each 
condition. 
 Linear regression analysis showed that probability of occurrence was a significant 
predictor of willingness to take the medication (F = 12.86, p < 0.0001) and perceived medication 
safety (F = 13.11, p < 0.0001) (see Table 2). Consistent with study hypotheses, participants were 
significantly less willing to take the medication when a high side-effect probability was given 
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compared to a low probability or no probability. Participants were significantly more likely to 
perceive the medication as safe in the low probability condition compared to the high probability 
and no probability condition.  Linear regression analyses showed that probability was also a 
significant predictor of the belief that medication benefits outweigh risks (F = 9.55, p < 0.0001), 
likelihood of the medication helping (F = 3.63, p < 0.05), likelihood of the medication causing 
side effects (F = 45.2, p < 0.0001), and likelihood of recommending the medication to others (F 
= 9.2, p = 0.0001). Participants in the high probability condition were less likely than those in the 
other two groups to agree that benefits outweigh the risks and that the medication was less likely 
to help. Participants in the low probability condition thought the medication was less likely to 
cause side effects and were more likely to recommend it to others compared to participants in the 
other two groups (see Table 2). 
Effect of Prevention Strategy Information 
 Linear regression analysis showed that prevention strategy information was a significant 
predictor of willingness to take the medication (F = 11.78, p < 0.0001) and perceived medication 
safety (F = 11.17, p < 0.0001) (Table 3). Consistent with study hypotheses, participants were 
significantly less willing to take the medication when no prevention strategy was given 
compared to prevention information with or without an explanation. Participants perceived the 
medication as least safe when no prevention strategy was given and safest when prevention 
strategy information was given. Participants who received a prevention strategy plus an 
explanation perceived the medication as safer than those who received no information but less 
safe than those who just received prevention information. Linear regression analyses also 
showed that prevention strategy information was a significant predictor for the belief that 
medication benefits outweigh risks (F = 12.03, p < 0.0001) and the likelihood of recommending 
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the medication to others (F = 7.61, p = 0.0005). Participants not given any prevention 
information were less likely to consider that the benefits of the medication outweigh the risks 
compared to participants in the other two groups. Participants not given any prevention 
information were also significantly less likely to recommend the medication to others compared 
to participants in the other two groups. There were no significant differences among the three 
groups for perceived likelihood of the medication helping or the likelihood of experiencing 
medication side-effects (see Table 3). 
Reasons for Willingness to Take the Medication 
 Table 4 shows the reasons participants gave for being likely or unlikely to use the 
medication. Only three of the six reasons revealed significant between group differences. 
Participants in the low probability condition were more likely to select any serious adverse 
events are very unlikely as their reason (x2(2) = 12.39, p = 0.002) compared to participants in the 
other two probability groups. Participants in the high probability condition were more likely than 
either of the other conditions to select a lot of people will get fungal infections and I don’t want 
to be one of them (x2(2) = 16.96, p = 0.0002). Participants given prevention information plus an 
explanation were most likely to choose the adverse events are not very serious as their reasoning 
for how likely or unlikely they would be to take the medication, followed by participants given 
just prevention information (x2(2) = 18.08, p < 0.0001). Participants not given any prevention 
information were more likely to choose a lot of people will get fungal infections and I don’t want 
to be one of them as their reasoning (x2(2) = 18.97, p < 0.0001). There were no significant 
between group differences among participants selecting prefer to avoid taking medications and 
will do something else, I would like to get rid of the wheezing and shortness of breath, and none 
of the above. 
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Discussion 
 Several important findings emerged from this study. First, the mean for all of the 
outcome variables in the group that was given no information regarding the probability of 
experiencing a fungal infection fell between the means observed in the high and low probability 
groups. Compared to participants in the low probability group, participants who received no 
probability information were less likely to: consider the medication safe, recommend the 
medication to others, and indicate that the low likelihood of serious adverse events was their 
primary reason for being willing to take the medication. They were also more likely than those in 
the low probability group to think the medication would cause side effects; however, they were 
not less willing to take the medication. These inconsistent findings may reflect uncertainty 
regarding the likelihood of adverse effects among those who received no probability information 
in this study, and it also shows that other factors are likely involved in patient decision-making 
regarding medication use. It is important to note that in real life practice, patients are rarely given 
numerical information regarding the likelihood of adverse effects. Therefore, the information 
given to participants in the non-numeric group most closely resembles that given to actual 
patients. Our findings suggest that, while patients may agree to take a medication even if they are 
not told the probability of adverse effects, they might have residual concerns about medication 
safety. In real life, this concern could manifest as premature medication discontinuation or lower 
adherence rates. This suggests that more specific counseling may be helpful for patients to 
correctly self-assess their own risk of experiencing adverse effects when taking a medication. 
This may be especially beneficial to those with adequate health literacy. Future research should 
examine whether providing patients with information concerning the probability of medication 
side-effects prior to the initiation of therapy leads to greater long-term adherence. 
12 
 
Second, providing participants with information concerning the prevention of fungal 
infections resulted in participants: being more willing to use the medication, perceiving that the 
medication was safer, indicating that medication benefits outweighed the risks, and being more 
likely to recommend the medication to others. As expected, prevention information had no effect 
on how likely the medication was perceived to help, as these two factors are unrelated. Providing 
prevention information also did not change the perceived likelihood of the medication causing 
side effects. Most likely this is because all participants except those in the non-numeric condition 
were given explicit information regarding the probability of the side-effect occurring. Although 
it is impossible for physicians and pharmacists to discuss every potential side-effect with 
patients, discussing prevention strategies for the more common side effects may be beneficial. 
Third, addition of an explanation for how the prevention strategy works affected only one 
of the outcome variables and this effect was in the opposite direction of that expected. That is, 
participants rated the medication as safer when an explanation was not given and only prevention 
information was provided. This may be because the explanation made the possibility of 
experiencing a fungal infection more salient to participants as they completed the questionnaire. 
Nonetheless, participants who received the explanation were more likely than those in the other 
two groups to indicate that their primary reason for being willing to take the medication was that 
the adverse effects were not very serious. It is possible this additional information may in fact be 
beneficial to patients with higher health literacy, and detrimental to those with lower health 
literacy. More research is needed to better understand how patients interpret information 
concerning the prevention of adverse events and how they utilize this information when making 
judgments and decisions concerning medication use. 
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Prior research comparing non-numerical information on adverse effect likelihood to 
numerical information showed that subjects given non-numerical information tend to be less 
willing to use a medication and more likely to overestimate the likelihood of the adverse effect 
(Blalock, 2016; Peters, 2014; Berry, 2004). Other research has assessed the combination of 
numerical and non-numerical information and found an overestimation of risk (Knapp, 2015). 
The present study took a different approach to previous research designs and compared the 
provision of numerical information to simply mentioning an adverse effect as being possible, 
which is consistent with most written medication information given to patients in the United 
States. We found that most participants in the non-numeric group estimated the likelihood of 
experiencing a fungal infection as between 3% and 15%. Additional research is needed to 
determine if, in the absence of numerical information, perceived probability estimates vary as a 
function of medication, adverse effect of interest, and patient characteristics.  
This study has several limitations that should be noted. First, real patients were not 
studied. Participants were recruited through a crowdsourcing internet marketplace and most were 
fairly young, relatively healthy, and well-educated. Thus, the generalizability of the study 
findings to a more typical patient population remains open to question. Second, participants read 
a hypothetical scenario that provided a limited amount of information. In an actual counseling 
session, pharmacists have the opportunity to tailor information on the basis of patient 
characteristics and patients have the chance to ask questions if information the pharmacist 
provides is unclear. In addition, non-verbal communication can facilitate patient understanding, 
and our study methods did not allow us to capture these types of effects. 
Despite these limitations, our findings suggest that providing patients with information 
regarding the probability of adverse effects and strategies to minimize potential risks may have a 
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significant, beneficial impact on patient perceptions of medication safety and their willingness to 
use a medication. It is already known that pharmacists are well-suited to help improve 
medication adherence and health outcomes. Prior research has shown that pharmacist-driven 
interventions can improve cardiovascular medication use, reduce cardiovascular-related medical 
expenses, and improve cardiovascular risk factors such as systolic and diastolic blood pressure 
(Bunting, 2008). Similar beneficial outcomes have been demonstrated with diabetes (Cranor, 
2003) and asthma (Bunting, 2006), as well. Further research is needed to specifically address the 
effect of adverse effect counseling on medication adherence, ideally within the context of real 
life clinical encounters. Ultimately, helping patients understand how to minimize medication 
risks may increase patient acceptance of therapeutic recommendations and enhance long-term 
adherence, leading to improved health outcomes. 
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Table 1. Additional Information Presented to Participants in Scenario Depending on 
Experimental Condition 
 
Probability 
Prevention Strategy 
No Information Prevention Strategy 
Only 
Prevention Strategy Plus 
Explanation 
 
No 
Information 
─ He says that these 
infections can be 
prevented by rinsing 
your mouth out with 
cool water after you 
use it. 
He says when the medication is 
inhaled, some of it gets stuck in the 
back of your throat and allows 
fungi to grow. Rinsing with water 
removes any of the medication 
stuck in your throat. 
 
 
 
 
Low 
 
 
He says that these 
infections occur 
in about 5% of 
people who use 
Cradulox. 
 
He says that these 
infections occur in 
about 5% of people 
who use Cradulox, 
but they can be 
prevented by rinsing 
your mouth out with 
cool water after you 
use it. 
He says that these infections occur 
in about 5% of people who use 
Cradulox, but they can be prevented 
by rinsing your mouth out with cool 
water after you use it. He says when 
the medication is inhaled, some of it 
gets stuck in the back of your throat 
and allows fungi to grow. Rinsing 
with water removes any of the 
medication stuck in your throat. 
 
 
 
 
High 
 
 
He says that these 
infections occur 
in about 20% of 
people who use 
Cradulox. 
 
He says that these 
infections occur in 
about 20% of people 
who use Cradulox, 
but they can be 
prevented by rinsing 
your mouth out with 
cool water after you 
use it. 
He says that these infections occur 
in about 20% of people who use 
Cradulox, but they can be prevented 
by rinsing your mouth out with cool 
water after you use it. He says when 
the medication is inhaled, some of it 
gets stuck in the back of your throat 
and allows fungi to grow. Rinsing 
with water removes any of the 
medication stuck in your throat. 
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Table 2. Means (SE) for Outcome Variables by Probability Condition. 
Outcome Variable No Probability Low Probability High Probability 
 
Likely to Take 
Medication 
 
4.77 (1.46)a 4.95 (1.36)a 4.21 (1.59)b 
Medication 
Safety 
 
4.19 (1.16)a 4.42 (1.04)b 3.82 (1.19)c 
Medication Benefits 
Outweigh Risks 
 
4.56 (1.37)a 4.79 (1.33)a 4.19 (1.39)b 
Medication Likely  
to Help 
 
5.05 (0.90)a 5.11 (0.88)a 4.87 (0.95)b 
Medication Likely to 
Cause Side Effects 
 
2.69 (1.36)a 1.73 (1.38)b 2.95 (1.32)a 
Likely to Recommend 
Medication 
 
3.52 (1.51)a 3.89 (1.39)b 3.25 (1.59)a 
______________________________________________________________________________ 
Note: conditions with different superscripts (‘a’, ‘b’, ‘c’) are significantly different from one 
another (p < 0.05). 
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Table 3. Means (SE) for Outcome Variables by Prevention Information Condition. 
 
Outcome Variable 
 
No Prevention 
Information 
 
Prevention 
Information 
Prevention 
Information and 
Rationale 
 
Likely to Take 
Medication 
 
4.23 (1.67)a 4.94 (1.27)b 4.75 (1.47)b 
Medication 
Safety 
 
3.85 (1.19)a 4.40 (1.05)b 4.17 (1.16)c 
Medication Benefits 
Outweigh Risks 
 
4.11 (1.46)a 4.71 (1.24)b 4.70 (1.38)b 
Medication Likely  
to Help 
 
4.90 (0.93) 5.06 (0.86) 5.06 (0.94) 
Medication Likely to 
Cause Side Effects 
 
2.48 (1.42) 2.39 (1.48) 2.48 (1.45) 
Likely to Recommend 
Medication 
 
3.21 (1.59)a 3.72 (1.47)b 3.74 (1.44)b 
______________________________________________________________________________ 
Note: conditions with different superscripts (‘a’, ‘b’, ‘c’) are significantly different from one 
another (p < 0.05). 
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Table 4. Most Important Reasons (%) for Willingness to Take Medication 
______________________________________________________________________________ 
   Probability Condition   Prevention Information Condition 
 
Reason 
No 
Probability 
(N = 202) 
Low 
Probability 
(N = 206) 
High 
Probability 
(N = 193) 
No 
Prevention 
Information 
(N = 191) 
Prevention 
Information 
(N = 209) 
Prevention 
Information and 
Explanation (N 
= 201) 
 
The adverse 
events are not 
very serious 
 
13.37 7.77 8.29 3.14a 10.05b 15.92c 
Any serious 
adverse events are 
unlikely 
 
21.78a 33.01b 18.65a 22.51 29.19 21.89 
Prefer to avoid 
taking 
medications 
 
9.41 8.25 9.84 7.33 8.13 11.94 
A lot of people 
will get fungal 
infections 
 
9.90a 6.80a 19.69b 20.42a 7.66b 8.46b 
Would like to get 
rid of wheezing 
and shortness of 
breath 
 
43.56 42.72 42.49 44.02 43.98 40.80 
None of the above 1.98 1.46 1.04 2.62 0.96 1.00 
______________________________________________________________________________
Note: conditions with different superscripts (‘a’, ‘b’, ‘c’) are significantly different from one 
another (p < 0.05). 
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